Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/10840
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Siderov, Jim | en |
dc.contributor.author | Duggan, John | en |
dc.date.accessioned | 2015-05-16T00:25:04Z | |
dc.date.available | 2015-05-16T00:25:04Z | |
dc.date.issued | 2009-06-12 | en |
dc.identifier.citation | Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners 2009; 16(2): 127-8 | en |
dc.identifier.govdoc | 19525303 | en |
dc.identifier.other | PUBMED | en |
dc.identifier.uri | https://ahro.austin.org.au/austinjspui/handle/1/10840 | en |
dc.description.abstract | Arsenic trioxide in the treatment of acute promyelocytic leukaemia is relatively safe with minimal side effects. Dental toxicities associated with its use are uncommon. We describe the first case report of toothache associated with arsenic trioxide. A 45-year-old male with relapsed APL was commenced on a treatment schedule of all-trans-retinoic acid 20mg four times a day for 14 days concurrent with a 10mg intravenous infusion of arsenic trioxide for 28 days. After 14 doses of the 6th cycle of treatment he experienced severe acute pain in various parts of the oral cavity. Extensive examination including an orthodontic review concluded there was no indication that the pain symptoms were due to a dental or endodontic cause. Four days after completing his 6th cycle the pain completely resolved. The mechanism of this adverse event remains unclear. Physicians with patients receiving arsenic trioxide with unexplained toothache should consider the arsenic as the cause of the pain. | en |
dc.language.iso | en | en |
dc.subject.other | Arsenicals.administration & dosage.adverse effects | en |
dc.subject.other | Humans | en |
dc.subject.other | Infusions, Intravenous | en |
dc.subject.other | Leukemia, Promyelocytic, Acute.drug therapy | en |
dc.subject.other | Male | en |
dc.subject.other | Middle Aged | en |
dc.subject.other | Oxides.administration & dosage.adverse effects | en |
dc.subject.other | Toothache.chemically induced.diagnosis | en |
dc.subject.other | Tretinoin.administration & dosage | en |
dc.title | Arsenic trioxide associated toothache. | en |
dc.type | Journal Article | en |
dc.identifier.journaltitle | Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners | en |
dc.identifier.affiliation | Cancer Services, Austin Health, Heidelberg, Victoria, Australia | en |
dc.identifier.doi | 10.1177/1078155209338727 | en |
dc.description.pages | 127-8 | en |
dc.relation.url | https://pubmed.ncbi.nlm.nih.gov/19525303 | en |
dc.type.austin | Journal Article | en |
local.name.researcher | Siderov, Jim | |
item.cerifentitytype | Publications | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.fulltext | No Fulltext | - |
item.openairetype | Journal Article | - |
item.grantfulltext | none | - |
item.languageiso639-1 | en | - |
crisitem.author.dept | Olivia Newton-John Cancer Wellness and Research Centre | - |
Appears in Collections: | Journal articles |
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.